Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
The DOI matches its Crossref record; 111 of the 112 references it cites were found in a registry or an index.
Abstract
Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Weight reduction, therefore, is a key therapeutic goal in both the prevention and management of type 2 diabetes (5).”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“Obesitydin particular abdominal obesitydis a major driver in the development of diabetes and cardiovascular disease (2), with the increasing prevalence of obesity mirrored by the rising prevalence of diabetes (3).”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“Orlistat was generally well tolerated, and gastrointestinal effects were the most commonly reported AEs, but all events were considered mild or moderate (75,76).”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Research works printed but not linked: 1
- Ferrannini, 2014, Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition, Diabetologia, 57, S8
Cited by
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031882 · Cited by 465
Leitner, D. R., Frühbeck, G., Yumuk, V., Schindler, K., Micic, D., Woodward, E., & Toplak, H. (2017) · Obesity Facts · doi:10.1159/000480525 · Cited by 431
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s008 · Cited by 244
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s008 · Cited by 244
Cefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s008 · Cited by 236
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s008 · Cited by 213
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12810 · Cited by 181
McCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I. (2020) · Diabetologia · doi:10.1007/s00125-019-05065-8 · Cited by 184
“Although many conventional glucose-lowering therapies may contribute to weight gain, treatment with GLP-1RAs and SGLT-2is has been associated with clinically meaningful weight loss [2].”
BackgroundInfluentialTreatment of adolescent obesity
Steinbeck, K. S., Lister, N. B., Gow, M. L., & Baur, L. A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0002-8 · Cited by 171
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s008 · Cited by 158
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 148
“for concerns, and the need for weight monitoring should be explained as a part of themedical evaluation process that helps to inform treatment decisions (23,24).”
BackgroundEmerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Vuksan, V., Jenkins, A. L., Brissette, C., Choleva, L., Jovanovski, E., Gibbs, A. L., Bazinet, R. P., Au-Yeung, F., Zurbau, A., Ho, H. V. T., et al. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.11.124 · Cited by 125
Ortega, M. A., Fraile-Martínez, O., Naya, I., García-Honduvilla, N., Álvarez-Mon, M., Buján, J., Asúnsolo, Á., & de la Torre, B. (2020) · Nutrients · doi:10.3390/nu12092749 · Cited by 115
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114
“Overweight and obesity are associated with elevated risk of type 2 diabetes mellitus (T2DM) (Van Gaal and Scheen, 2015).”
Aras, M., Tchang, B. G., & Pape, J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.008 · Cited by 108
SGLT2 Inhibitors: Benefit/Risk Balance
Scheen, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0789-4 · Cited by 119
Self-citationMahil, S. K., McSweeney, S. M., Kloczko, E., McGowan, B. M., Barker, J. N., & Smith, C. H. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17741 · Cited by 114
Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ
Zhou, Q., Sun, W.-W., Chen, J.-C., Zhang, H.-L., Liu, J., Lin, Y., Lin, P., Wu, B., An, Y., Huang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32000-0 · Cited by 119
Yan, Y., Sha, Y., Yao, G., Wang, S., Kong, F., Liu, H., Zhang, G., Zhang, H., Hu, C., & Zhang, X. (2016) · Medicine · doi:10.1097/md.0000000000003462 · Cited by 94
van Ommen, B., Wopereis, S., van Empelen, P., van Keulen, H. M., Otten, W., Kasteleyn, M. J., Molema, J. J. W., de Hoogh, I. M., Chavannes, N. H., Numans, M. E., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00381 · Cited by 95
“(Chronic) Calorie Restriction There is no doubt that caloric restriction and weight loss ameliorate metabolic anomalies in patients with T2D (47, 48).”
Cernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 84
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 165
Blonde, L., Stenlöf, K., Fung, A., Xie, J., Canovatchel, W., & Meininger, G. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1169894 · Cited by 71
“[5–7] In addition, weight loss has been associated with improvements in glycemic control.[1,5]”
BackgroundSGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“[21] In a cross-over study in healthy volunteers, canagliflozin 300 mg provided significantly smaller postprandial glucose excursions than dapagliflozin 10 mg.[22] This additional effect might at least partially (besides the reduction of the glucotoxicity) explain why treatment with canagliflozin improved model-based…”
BackgroundResultInfluentialSelf-citationPharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
Zhou, K., Pedersen, H., Dawed, A. Y., & Pearson, E. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.51 · Cited by 78
Verhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 87
Noronha, J. C., Nishi, S. K., Braunstein, C. R., Khan, T. A., Blanco Mejia, S., Kendall, C. W. C., Kahleová, H., Rahelić, D., Salas-Salvadó, J., Leiter, L. A., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2270 · Cited by 65
Foster, D., Sanchez-Collins, S., & Cheskin, L. J. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0045 · Cited by 79
“Both view weight as an indirect indicator of metabolic disease, cardiovascular disease, and poor quality of life (32); in the later stages of diabetes, however, the emphasis may shift from weight loss to glucocentric strategies while avoiding further weight gain.”
BackgroundNam, G. E., Park, Y. G., Han, K., Kim, M. K., Koh, E. S., Kim, E. S., Lee, M., Kim, B., Hong, O., & Kwon, H. (2019) · Diabetes Care · doi:10.2337/dc18-1667 · Cited by 67
“Although these parameters have clinical implications in the prevention and treatment of type 2 diabetes (17), there are limited data on the association between baseline BMI, weight change, and the risk of incident dementia in patients with type 2 diabetes.”
BackgroundIs Bariatric Surgery an Effective Treatment for Type II Diabetic Kidney Disease?
Friedman, A. N., & Wolfe, B. M. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07670715 · Cited by 65
“Similarly, pharmacotherapy for obesity offers similarly modest average weight loss results (15) with added safety concerns (16).”
BackgroundKhalili, L., Alipour, B., Jafarabadi, M. A., Hassanalilou, T., Abbasi, M. M., & Faraji, I. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0400-7 · Cited by 67
RetractedCanagliflozin: A Review in Type 2 Diabetes
Deeks, E. D., & Scheen, A. J. (2017) · Drugs · doi:10.1007/s40265-017-0801-6 · Cited by 66
“DPP4 inhibitors, metformin, a-glucosidase inhibitors) [2, 95]; as such, canagliflozin has a bodyweight profile more favourable than that of glimepiride or sitagliptin as an add-on therapy (Sect.”
BackgroundSelf-citationPrecision medicine: The future in diabetes care?
Scheen, A. J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.033 · Cited by 60
“Therefore, besides high body mass index, the presence of atherogenic dyslipidaemia (hypertriglyceridaemia, low HDL) should favour the prescription of agents that can promote weight loss (and thus reduce abdominal adiposity) (SGLT-2 inhibitors, GLP-1 receptor agonists) and/or improve insulin resistance (pioglitazone) […”
BackgroundSelf-citationVerhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
“In patients who are obese or those with diabetes, GLP-1 RA demonstrates long-lasting weight loss and benefits on glucose metabolism [1, 3].”
BackgroundShao, S., Chang, K., Lin, S.-J., Chien, R., Hung, M., Chan, Y., Yang, Y. K., & Lai, E. C. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0990-2 · Cited by 62
Pharmacological Approaches in the Treatment and Maintenance of Weight Loss
Van Gaal, L., & Dirinck, E. (2016) · Diabetes Care · doi:10.2337/dcs15-3016 · Cited by 52
“weight effects of pharmacotherapy in the management of obesity-related comorbidities and consider weight-neutral or weight-reducing medications that can complement the patient’s desire for a healthier lifestyle (60).”
BackgroundJanež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
Ahn, E., Lee, J., Jeon, Y.-H., Choi, S., & Kim, E. (2017) · Food Science and Biotechnology · doi:10.1007/s10068-017-0223-y · Cited by 52
Samuel‐Hodge, C. D., Holder, J. C., Gizlice, Z., Davis, G., Steele, S. P., Keyserling, T. C., Kumanyika, S., Brantley, P. J., & Svetkey, L. P. (2016) · Obesity · doi:10.1002/oby.21700 · Cited by 53
“4 Diabetes treated with insulin, n (%) 13 (24) 7 (19) 6 (33) Diagnosed hypertension, n (%) 42 (78) 28 (52) 30 (83) 18 (50) 12 (67) 10 (56) Lifestyle, diabetes self-care, family interactions Moderate-intensity PA (min/wk) 95.”
BackgroundSeidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Lutes, L. D., Cummings, D. M., Littlewood, K., DiNatale, E., & Hambidge, B. (2017) · Obesity · doi:10.1002/oby.21883 · Cited by 47
“Additionally, through post hoc exploratory analyses, we sought to identify factors that may impact weight trajectory over 12 months, including insulin use, as it is known to mediate treatment outcome (34).”
MethodA comprehensive review on the glucoregulatory properties of food-derived bioactive peptides
Jahandideh, F., Bourque, S. L., & Wu, J. (2022) · Food Chemistry X · doi:10.1016/j.fochx.2022.100222 · Cited by 49
Rashid, M., Shahzad, M., Mahmood, S., & Khan, K. (2018) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.35.1.100 · Cited by 45
Khalafi, M., Symonds, M. E., & Akbari, A. M. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1873732 · Cited by 52
Khalafi, M., Symonds, M. E., Maleki, A. H., Sakhaei, M. H., Ehsanifar, M., & Rosenkranz, S. K. (2024) · Nutrition Journal · doi:10.1186/s12937-023-00909-x · Cited by 56
Reversal and Remission of T2DM – An Update for Practitioners
Shibib, L., Al-Qaisi, M., Ahmed, A., Miras, A. D., Nott, D., Pelling, M., Greenwald, S. E., & Guess, N. D. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s345810 · Cited by 48
Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism
Verhaegen, A. A., & Gaal, L. F. V. (2019) · Europe PMC (PubMed Central) · Cited by 53
Khalafi, M., Sakhaei, M. H., Kazeminasab, F., Rosenkranz, S. K., & Symonds, M. E. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.024 · Cited by 51
Umpierrez, G. E., Pantalone, K. M., Kwan, A. Y. M., Zimmermann, A. G., Zhang, N., & Fernández Landó, L. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12660 · Cited by 36
“E-mail: geumpie@emory.edu This is an open access article under the terms of the Creative Commons AttributionNonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. options add…”
BackgroundInfluentialPharmacotherapy of ‘treatment resistant’ type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297424 · Cited by 40
“Several recently developed antiobesity agents are commercialized in the US but not in Europe yet (Table 1) [44].”
BackgroundSelf-citationDhakal, S., McCormack, L. A., & Dey, M. (2020) · Microorganisms · doi:10.3390/microorganisms8081246 · Cited by 40
“Ironically, losing weight is particularly challenging for individuals with type 2 diabetes [63].”
BackgroundFleury, L., Deracinois, B., Dugardin, C., Nongonierma, A. B., Fitzgerald, R. J., Flahaut, C., Cudennec, B., & Ravallec, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158365 · Cited by 40
“peripheral tissues (liver, muscle) [3,4].”
BackgroundKullgren, J. T., Hafez, D., Fedewa, A., & Heisler, M. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0894-z · Cited by 43
Gu, Y., Dennis, S. M., Kiernan, M. C., & Harmer, A. R. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3099 · Cited by 38
Nederveen, J. P., Mastrolonardo, A. J., Xhuti, D., Di Carlo, A., Manta, K., Fuda, M. R., & Tarnopolsky, M. A. (2023) · Nutrients · doi:10.3390/nu15173693 · Cited by 33
Wang, H., Yang, J., Chen, X., Qiu, F., & Li, J. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.01.001 · Cited by 36
When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
Avogaro, A., Delgado, E., & Lingvay, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2981 · Cited by 35
“Substantial weight loss though diet and lifestyle changes is difficult to achieve and sustain.(42) Older glucose lowering agents (sulfonylureas, thiazolidinediones, glinides, and insulin) exacerbate this situation by promoting weight gain.”
BackgroundXie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 36
Current State of Bariatric Surgery: Procedures, Data, and Patient Management
Rogers, A. M. (2020) · Techniques in vascular and interventional radiology · doi:10.1016/j.tvir.2020.100654 · Cited by 36
High-Protein Diets for Treatment of Type 2 Diabetes Mellitus: A Systematic Review
Malaeb, S., Bakker, C., Chow, L. S., & Bantle, A. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz002 · Cited by 34
“For example, even in the controlled setting of an intensive lifestyle intervention trial for T2D, half of all patients who lost >5% of their weight by year 1 regained some or all of this weight by year 8 (4).”
BackgroundButala, M. A., Kukkupuni, S. K., & Vishnuprasad, C. N. (2017) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2017.03.005 · Cited by 28
“cross-talk between diabetes and obesity, the choices of drugs suitable for combined treatment of diabetes and obesity are limited in modern medicine [3].”
BackgroundKasar, K. S., Aşiret, G. D., Yılmaz, C. K., & Canlar, Ş. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.09.005 · Cited by 37
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 28
Self-citationEpidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“Along with single-drug therapies, several combination therapies are being explored since complementary drug combinations can overcome counterregulatory responses, allow lower doses to be used, minimize the adverse effects, and thus become beneficial for the management of obesity (Table 5).(214,215) Along those lines,…”
BackgroundDiedisheim, M., Poitou, C., Genser, L., Amouyal, C., Bouillot, J., Ciangura, C., Oppert, J., Clément, K., & Aron‐Wisnewsky, J. (2020) · Obesity Surgery · doi:10.1007/s11695-020-05075-1 · Cited by 28
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?—A Review of Intervention Studies
Uldal, S., Clemmensen, K. K. B., Persson, F., Færch, K., & Quist, J. S. (2022) · Nutrients · doi:10.3390/nu14112299 · Cited by 28
Raubenheimer, J., Myburgh, P. H., & Bhagavathula, A. S. (2024) · BMC Global and Public Health · doi:10.1186/s44263-024-00095-w · Cited by 41
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 27
“gave rather disappointing results until now, even if some new opportunities are emerging [101].”
BackgroundResultSelf-citationClinical pharmacology of imeglimin for the treatment of type 2 diabetes
Johansson, K. S., Brønden, A., Knop, F. K., & Christensen, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1729123 · Cited by 31
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 24
Kaur, K. K., Allahbadia, G. N., & Singh, M. (2019) · Obesity Research - Open Journal · doi:10.17140/oroj-6-136 · Cited by 26
Cheng, A. K. S., Yeoh, E. C. K., Moh, A. M. C., Low, S. K., Tan, C. H., Lam, B. C. C., Sum, C. F., Subramaniam, T., & Lim, S. C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109900 · Cited by 24
Rodbard, H. W., Bellary, S., HRAMIAK, I. M., Seino, Y., Silver, R., Damgaard, L. H., Nayak, G., Zacho, J., & Aroda, V. R. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0444 · Cited by 20
Cheung, L. T. F., Ko, G. T. C., Chow, F. C. C., & Kong, A. P. S. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12800 · Cited by 29
The Role of Bariatric Surgery on Diabetes and Diabetic Care Compliance
Jackson, H. T., Anekwe, C. V., Chang, J., Haskins, I. N., & Stanford, F. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1236-0 · Cited by 22
Watson, N. A., Dyer, K. A., Buckley, J. D., Brinkworth, G. D., Coates, A. M., Parfitt, G., Howe, P. R. C., Noakes, M., & Murphy, K. J. (2018) · Nutrition Research · doi:10.1016/j.nutres.2018.05.005 · Cited by 19
Medveczky, D., Kodsi, R., Skelsey, K., Grudzinskas, K., Bueno, F. R., Ho, V., Kormas, N., & Piya, M. K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9327910 · Cited by 21
Yoshida, Y., Hong, D., Nauman, E., Price-Haywood, E. G., Bazzano, A. N., Stoecker, C., Hu, G., Shen, Y., Katzmarzyk, P. T., Fonseca, V. A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002136 · Cited by 15
Chang, Z., Xu, J., Qin, Y., Zheng, Q., Zhao, L., Wang, Y., & Zhang, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282143 · Cited by 17
“The foundation of T2DM management is to maintain a healthy lifestyle and an appropriate body weight [7].”
BackgroundShinde, S., Thieu, V. T., Kwan, A. Y. M., Houghton, K., Meyers, J., & Schapiro, D. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01511-4 · Cited by 19
Ma, R., Weng, H., & Liang, J. (2016) · Journal of Separation Science · doi:10.1002/jssc.201600924 · Cited by 15
Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0783-4 · Cited by 16
“In terms of bodyweight, metformin, GLP-1 receptor agonists and SGLT2 inhibitors are associated with beneficial effects and DPP-4 inhibitors and a-glucosidase inhibitors with neutral effects, whereas sulfonylureas, meglitinides, thiazolidinediones and insulin therapies all increase the risk of bodyweight gain [3, 32].”
BackgroundAdu, E. A., Obirikorang, C., Acheampong, E., Kwakye, A. S., Fokuoh, F., Obirikorang, Y., Anto, E. O., Batu, E. N., Amoah, B. Y., & Ansong, P. N. (2019) · Cogent Medicine · doi:10.1080/2331205x.2019.1639880 · Cited by 15
“Also, among T2DM patients, in addition to the many conventional glucose-lowering agents associated with weight gain (Group, 1998; Van Gaal & Scheen, 2015), metabolic, psychological, and behavioural factors also influence weight gain among T2DM patients (Cabrera et al., 2012; Toft et al., 2006).”
BackgroundSchernthaner, G., Lavalle-Gonzalez, F. J., Davidson, J. A., Jodon, H., Vijapurkar, U., Qiu, R., & Canovatchel, W. J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1210988 · Cited by 13
“Thus, antihyperglycemic agents (AHAs) that lower both HbA1c and body weight may be beneficial in patients with T2DM who are unable to achieve weight loss through lifestyle modification alone [5].”
BackgroundThree-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
Trautmann, M., van Gaal, L., Han, J., & Hardy, E. (2017) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2017.06.004 · Cited by 12
“It is well known that obesity contributes to progression of diabetes complications and can be a risk factor for cardiovascular events in patients with T2D (Van Gaal & Scheen, 2015; Van Gaal, et al., 2006).”
InfluentialJensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., Vovk, A., & Janež, A. (2021) · Trials · doi:10.1186/s13063-021-05442-y · Cited by 14
Kang, E. (2021) · Workplace Health & Safety · doi:10.1177/2165079920986160 · Cited by 15
“In addition, proper sleep and weight management may also affect the management of chronic diseases (Cohen, 2017; Igel et al., 2018; Thomas & Calhoun, 2017; Van Gaal & Scheen, 2015).”
BackgroundPersonality and weight management in adults with type 2 diabetes: A systematic review
Geerling, R. H., Kothe, E. J., Anglim, J., Emerson, C., Holmes‐Truscott, E., & Speight, J. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.1044005 · Cited by 16
Metadata
- Authors
- Van Gaal, L., & Scheen, A.
- Affiliations
- Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium
- University of Liège (BE)
- ORCID
- Scheen, André
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-05-12
- Volume
- 38
- Issue
- 6
- Pages
- 1161-1172
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1893948433
- Cited by
- 221
- References
- 112
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 22 · 2023: 19 · 2022: 17 · 2021: 18 · 2020: 24 · 2019: 23 · 2018: 22 · 2017: 27 · 2016: 24 · 2015: 8
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, obesity, weight management, weight loss, pharmacotherapy, glucose-lowering medications, anti-obesity drugs, glycemic control, combination therapy, lifestyle intervention
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Forecasting, Humans, Hypoglycemic Agents, Obesity, Weight Gain, Weight Loss, Anti-Obesity Agents, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.